Foresite Capital Management IV, LLC Diversified Active

CIK: 0001704132 · Show all filings

Period: Q1 2023 (← Previous) (Next →)

Filing Date: May 12, 2023

Total Value ($000): $192,724 (100.0% shares, 0.0% debt)

Holdings (8)

— Kinnate Biopharma Inc. 31.4%

Value ($000) $60,448 Shares 9,671,643 Est. Cost $39.78 Unrealized —

PHVS Pharvaris N.V. 13.6%

Value ($000) $26,154 Shares 3,246,926 Est. Cost $31.46 Unrealized -72.0%

— Lyell Immunopharma, Inc. 12.2%

Value ($000) $23,600 Shares 10,000,000 Est. Cost $16.24 Unrealized —

ACRS Aclaris Therapeutics, Inc. 11.8%

Value ($000) $22,717 Shares 2,808,034 Est. Cost $15.18 Unrealized -16.4%

KURA Kura Oncology, Inc. 11.7%

Value ($000) $22,625 Shares 1,849,947 Est. Cost $20.39 Unrealized -38.8%

SNDX Syndax Pharmaceuticals, Inc. 9.6%

Value ($000) $18,480 Shares 875,000 Est. Cost $22.62 Unrealized +10.0%

— Cymabay Therapeutics, Inc. 8.1%

Value ($000) $15,583 Shares 1,787,094 Est. Cost $3.49 Unrealized —

QSI Quantum-Si Incorporated 1.6%

Value ($000) $3,117 Shares 1,771,249 Est. Cost $10.48 Unrealized -81.2%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Kinnate Biopharma Inc.	9,671,643	$60,448	31.4%	$39.78	—	COM	49705R105
PHVS	Pharvaris N.V.	3,246,926	$26,154	13.6%	$31.46	-72.0%	COM	N69605108
—	Lyell Immunopharma, Inc.	10,000,000	$23,600	12.2%	$16.24	—	COM	55083R104
ACRS	Aclaris Therapeutics, Inc.	2,808,034	$22,717	11.8%	$15.18	-16.4%	COM	00461U105
KURA	Kura Oncology, Inc.	1,849,947	$22,625	11.7%	$20.39	-38.8%	COM	50127T109
SNDX	Syndax Pharmaceuticals, Inc.	875,000	$18,480	9.6%	$22.62	+10.0%	COM	87164F105
—	Cymabay Therapeutics, Inc.	1,787,094	$15,583	8.1%	$3.49	—	COM	23257D103
QSI	Quantum-Si Incorporated	1,771,249	$3,117	1.6%	$10.48	-81.2%	COM CL A	74765K105